Amplia Therapeutics - CEO and MD, Dr John Lambert
CEO and MD, Dr John Lambert
Source: Amplia Therapeutics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Amplia Therapeutics (ATX) completes manufacture of its clinical-stage drug candidate ahead of planned trials
  • A two-kilogram batch of the company’s AMP945 will be used in toxicology studies and phase two clinical trials in pancreatic cancer and lung fibrosis
  • Amplia implemented improvements to the manufacturing process and doubled the batch size of previous production
  • The phase two clinical trial of AMP945 in patients with pancreatic cancer remains on track to kick off this quarter
  • ATX shares leap 12.5 per cent to 18 cents

Amplia Therapeutics (ATX) shares have climbed after the company manufactured a batch scale of its clinical-stage drug candidate AMP945 ahead of planned clinical trials and toxicology studies in pancreatic cancer and lung fibrosis.

The two-kilogram Good Manufacturing Practice (GMP)-approved product was completed within Amplia’s budget and schedule.

It was manufactured for Amplia’s phase two clinical trials and toxicology studies in pancreatic cancer and lung fibrosis, which are due to start during 2022.

The company said that during the AMP945 manufacturing run, it implemented improvements to the manufacturing process to help underpin future clinical and commercial development.

Prior to this, the maximum batch size of AMP945 had been one kilogram. Amplia said it had since demonstrated the scale at which AMP945 was manufactured under GMP conditions could be doubled.

 “The successful doubling of our manufacturing capacity for clinical-grade AMP945 and the implementation of manufacturing improvements are outstanding outcomes which have exceeded our initial expectations,” Amplia CEO Dr John Lambert said.

“As well as providing material for our near-term development programs, these improvements lay a strong foundation for the AMP945 data package that will be required for future regulatory applications and its commercial development.”

According to the company, long-term stability testing data showed AMP945 could be stored for longer than 24 months without detectable deterioration, which it suggested further supported the potential commercial development of AMP945.

Amplia said its phase two clinical trial of AMP945 in patients suffering pancreatic cancer remained on track to commence this quarter.

The extended toxicology studies required to support a clinical trial of AMP945 in patients with fibrotic lung disease were also on schedule to begin in February.

ATX shares were trading 12.5 per cent higher at 18 cents at 12:49 pm AEDT.

ATX by the numbers
More From The Market Herald
Limeade (ASX:LME) - CEO, Henry Albrecht

" Limeade (ASX:LME) maintains FY21 financial guidance in quarterly report

Limeade (ASX:LME) has maintained its FY21 revenue guidance of $50 million to $53 million, but posted…
Sihayo Gold (ASX:SIH) - Executive Chairman, Colin Moorhead

" Sihayo Gold (ASX:SIH) secures further interim funding

Sihayo Gold (ASX:SIH) has secured interim funding from its shareholder, PT Saratoga Investama Sedaya Tbk.

" Alchemy Resources (ASX:ALY) commences aircore drilling at Karonie

Aircore drilling is underway at Alchemy Resources' (ASX:ALY) Karonie gold project 110 kilometres east of Kalgoorlie,…
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece